Investigational anabolic therapies for osteoporosis

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

(2010) Sutada Lotinun et al.   BONE

Anabolics in Osteoporosis: The Emerging Therapeutic Tool

(2010) R. Trivedi et al.   CURRENT MOLECULAR MEDICINE

Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats

(2010) Cedo M. Bagi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Parathyroid Hormone-Related Protein for the Treatment of Postmenopausal Osteoporosis: Defining the Maximal Tolerable Dose

(2010) Mara J. Horwitz et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The discovery of novel calcium sensing receptor negative allosteric modulators

(2009) Gayatri Balan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women

(2009) Silvano Adami et al.   BONE

An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation

(2009) Sanjay Kumar et al.   BONE

Prevention of osteoporosis-related fractures among postmenopausal women and older men

(2009) P. Rahmani et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Wnt signaling as a therapeutic target for bone diseases

(2009) Luke H Hoeppner et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The relationships among bone health, insulin-like growth factor-1 and sex hormones in adolescent female athletes

(2009) Rita Gruodytė et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Functional α1- and β2-adrenergic receptors in human osteoblasts

(2009) H.H. Huang et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin

(2009) Kristy M. Nicks et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

β2-Adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms

(2008) Sarah J. Aitken et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum

(2008) Vijay K. Yadav et al.   CELL

Recent Updates on the Calcium-Sensing Receptor as a Drug Target

(2008) Ritu Trivedi et al.   CURRENT MEDICINAL CHEMISTRY

BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway

(2008) N. Kamiya et al.   DEVELOPMENT

Structural Insight into the Mechanisms of Wnt Signaling Antagonism by Dkk

(2008) Lijun Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women*

(2008) Jon Ruckle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*

(2008) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions

(2008) N. Bonnet et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Relationship among insulinlike growth factor I concentrations, bone mineral density, and biochemical markers of bone turnover in postmenopausal women

(2008) Iraj Nabipour et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity

(2008) R. S. Pearsall et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA